Symptomatic treatment: iterative vertigo with or without sign, cochlear


This form is reserved for patients requiring a dosage of 48 mg per day of betahistine. In other cases, use a lower dosage

BETAHISTINE RANBAXY 24 mg tablets will be given 1 tablet twice daily, preferably in the middle of the meal.
Processing time

The duration of the recommended treatment is 2 to 3 months, to be renewed, possibly according to the evolution of the disease, in continuous or discontinuous cures.
Mode of administration

The tablets must be swallowed without being crunched with a glass of water.

Class: Pharmacotherapeutic: ANTIVERTIGINOUS.

Code: ATC: N07CA01.

The mechanism of action of betahistine is partially known.

In vitro, betahistine, facilitates histaminergic transmission by its agonist effect, partial on the H 1 receptors, and an effect, antagonist of receptors of type H 3.
< Code>
Betahistin decreases, electrical activity of polysynaptic neurons, vestibular nuclei after I.V. administration in the animal

Betahistine has no effect sedative

Not applicable.

· Hypersensitivity to any of the components of this medication

· Gastroduodenal ulcer in thrust

· Pheochromocytoma.

In asthmatics, administration of betahistine requires special surveillance (risk of bronchoconstriction).

Betahistine does not constitute the appropriate treatment of the following diseases

· Benign paroxysmal vertigo

· Vertigo in relation to a nervous system disorder,

Because of the presence of lactose, this drug is contraindicated in cases of galactosemia, congenital, glucose and galactose malabsorption syndrome or lactase deficiency. >

Not applicable.

Not applicable.

· Symptoms similar to those caused by histamine

· Administer antihistamine treatment.


Studies in the animal have not demonstrated any teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals during studies, well conducted on two species
< Br>

There are currently no relevant or sufficient data to evaluate a possible malformative or fetotoxic effect of betahistin when administered during pregnancy

Therefore, as a precautionary measure, it is preferable not to use betahistin during pregnancy.

In the absence of data on the passage through breast milk, the risk is not known, therefore breast-feeding is not recommended, while taking betahistine.

· Most common adverse reactions: gastralgia, nausea, vomiting, dry mouth, diarrhea

· More rarely: headache, asthenia, drowsiness, hypersensitivity reactions

· Exceptionally: thrombocytopenia, elevation, transaminases.

Symptomatic treatment: iterative vertigo with or without sign, cochlear